William A. Biermann

1.9k total citations · 2 hit papers
12 papers, 1.4k citations indexed

About

William A. Biermann is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, William A. Biermann has authored 12 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Surgery and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in William A. Biermann's work include Pancreatic and Hepatic Oncology Research (6 papers), Cancer Genomics and Diagnostics (4 papers) and Neuroendocrine Tumor Research Advances (3 papers). William A. Biermann is often cited by papers focused on Pancreatic and Hepatic Oncology Research (6 papers), Cancer Genomics and Diagnostics (4 papers) and Neuroendocrine Tumor Research Advances (3 papers). William A. Biermann collaborates with scholars based in United States and Canada. William A. Biermann's co-authors include Natasha B. Leighl, Suresh S. Ramalingam, Mohammed Mohiuddin, Francis E. Rosato, Donna J. Barbot, Ishmael Jaiyesimi, Giuseppe Giaccone, David H. Johnson, Joan H. Schiller and Bryan J. Schneider and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

William A. Biermann

12 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

2017 471 citations Nasser H. Hanna, David H. Johnson et al. Journal of Clinical Oncology profile →
Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update

2018 342 citations Gregory P. Kalemkerian, Navneet Narula et al. Journal of Clinical Oncology profile →

Peers

William A. Biermann

PRM

ONCOL

EPIDE

J. Bonneterre France

Epaminontas Samantas Greece

Fausto Barbieri Italy

J.M.G.H. van Riel Netherlands

Agnese Montanino Italy

Fumiyoshi Ohyanagi Japan

C. A. Angeletti Italy

Jean-Louis Pujol France

M. Duruisseaux France

Andrea Marchetti Italy

J. Bonneterre France

William A. Biermann

462 ×0.5

PRM

764 ×0.9

ONCOL

464 ×1.0

224 ×0.9

85 ×0.6

EPIDE

Citations per year, relative to William A. Biermann William A. Biermann (= 1×) peers J. Bonneterre

Countries citing papers authored by William A. Biermann

Since Specialization

Citations

This map shows the geographic impact of William A. Biermann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William A. Biermann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William A. Biermann more than expected).

Fields of papers citing papers by William A. Biermann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William A. Biermann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William A. Biermann. The network helps show where William A. Biermann may publish in the future.

Co-authorship network of co-authors of William A. Biermann

This figure shows the co-authorship network connecting the top 25 collaborators of William A. Biermann. A scholar is included among the top collaborators of William A. Biermann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William A. Biermann. William A. Biermann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Kalemkerian, Gregory P., Navneet Narula, Erin B. Kennedy, et al.. (2018). Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. Journal of Clinical Oncology. 36(9). 911–919. 342 indexed citations breakdown →

Hanna, Nasser H., David H. Johnson, Sarah Temin, et al.. (2017). Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology. 35(30). 3484–3515. 471 indexed citations breakdown →

Leighl, Natasha B., Natasha Rekhtman, William A. Biermann, et al.. (2014). Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline. Journal of Clinical Oncology. 32(32). 3673–3679. 217 indexed citations

Mohiuddin, Mohammed, et al.. (1995). Combined intraoperative radiation and perioperative chemotherapy for unresectable cancers of the pancreas.. Journal of Clinical Oncology. 13(11). 2764–2768. 81 indexed citations

Mohiuddin, Mohammed, et al.. (1994). Carcinoma of the pancreas--the Jefferson experience 1975-1988.. PubMed. 20(1). 13–20. 15 indexed citations

Mohiuddin, M., et al.. (1993). Intraoperative radiotherapy in the combined modality management of pancreatic cancer. International Journal of Radiation Oncology*Biology*Physics. 27. 279–279. 2 indexed citations

Mohiuddin, Mohammed, et al.. (1992). Long-term results of combined modality treatment with I-125 implantation for carcinoma of the pancreas. International Journal of Radiation Oncology*Biology*Physics. 23(2). 305–311. 49 indexed citations

Vetter, G, et al.. (1989). [Shortening diclofenac therapy by B vitamins. Results of a randomized double-blind study, diclofenac 50 mg versus diclofenac 50 mg plus B vitamins, in painful spinal diseases with degenerative changes].. PubMed. 47(5). 351–62. 24 indexed citations

Mohiuddin, Mohammed, et al.. (1988). Combined modality treatment of localized unresectable adenocarcinoma of the pancreas. International Journal of Radiation Oncology*Biology*Physics. 14(1). 79–84. 61 indexed citations

10.

Biermann, William A., et al.. (1985). Evaluation of Cisplatin-Lithium Interaction. Drug Intelligence & Clinical Pharmacy. 19(1). 31–32. 5 indexed citations

11.

Whittington, Richard, Lawrence J. Solin, Mohammed Mohiuddin, et al.. (1984). Multimodality therapy of localized unresectable pancreatic adenocarcinoma. Cancer. 54(9). 1991–1998. 78 indexed citations

12.

Haurani, Farid I., Carl G. Kardinal, & William A. Biermann. (1978). Thymidylate synthetase and dihydrofolic acid reductase in the stimulated human lymphocyte. Journal of Cellular Physiology. 95(1). 49–55. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact